One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection

Joseph B. Bavaro, Linda Drolette, David M. Koelle, Jennifer Almekinder, Terri Warren, Stephen Tyring, Anna Wald*

*Corresponding author for this work

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration and severity of genital herpes recurrences and to measure the frequency of viral shedding episodes subsequent to antiviral therapy. STUDY DESIGN: In an open-label pilot study, patients with recurrent genital herpes simplex virus 2 (HSV-2) infection were given a 1-day course of valacyclovir (2000 mg given by mouth twice daily) to be taken at the first sign of recurrence or prodrome. Participants maintained diaries of signs and symptoms and collected genital swabs for viral culture while lesions persisted and HSV DNA PCR for 14 days after initiating treatment. RESULTS: Ninety (78%; 41 men, 49 women) of the 115 enrolled persons experienced either a lesional recurrence or prodrome. Seventy- seven (86%) participants developed lesions; 4 (5%) participants experienced a second lesional recurrence during the 14-day study period. The median lesion duration was 5 days, episode duration was 5 days, and pain duration was 3 days. Viral shedding was detected in 60 persons by PCR and 31 persons by culture. Shedding detected by culture lasted for a median of 2 days, and shedding detected by PCR lasted for a median of 3 days. Of 60 participants with viral shedding, 14 (23%) had an additional shedding episode after their initial lesion healed, lasting for a median of 2 days. CONCLUSIONS: A 1-day course of valacyclovir may be a convenient treatment for recurrent genital herpes and comparative trials are warranted.

Original languageEnglish (US)
Pages (from-to)383-386
Number of pages4
JournalSexually Transmitted Diseases
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

valacyclovir
Herpes Genitalis
Human Herpesvirus 2
Virus Diseases
Virus Shedding
Recurrence
Polymerase Chain Reaction
Therapeutics
Signs and Symptoms
Antiviral Agents
Mouth
Pain
DNA

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Bavaro, Joseph B. ; Drolette, Linda ; Koelle, David M. ; Almekinder, Jennifer ; Warren, Terri ; Tyring, Stephen ; Wald, Anna. / One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. In: Sexually Transmitted Diseases. 2008 ; Vol. 35, No. 4. pp. 383-386.
@article{4f63d3f9094b41819c2da4f29c15ed5c,
title = "One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection",
abstract = "OBJECTIVES: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration and severity of genital herpes recurrences and to measure the frequency of viral shedding episodes subsequent to antiviral therapy. STUDY DESIGN: In an open-label pilot study, patients with recurrent genital herpes simplex virus 2 (HSV-2) infection were given a 1-day course of valacyclovir (2000 mg given by mouth twice daily) to be taken at the first sign of recurrence or prodrome. Participants maintained diaries of signs and symptoms and collected genital swabs for viral culture while lesions persisted and HSV DNA PCR for 14 days after initiating treatment. RESULTS: Ninety (78{\%}; 41 men, 49 women) of the 115 enrolled persons experienced either a lesional recurrence or prodrome. Seventy- seven (86{\%}) participants developed lesions; 4 (5{\%}) participants experienced a second lesional recurrence during the 14-day study period. The median lesion duration was 5 days, episode duration was 5 days, and pain duration was 3 days. Viral shedding was detected in 60 persons by PCR and 31 persons by culture. Shedding detected by culture lasted for a median of 2 days, and shedding detected by PCR lasted for a median of 3 days. Of 60 participants with viral shedding, 14 (23{\%}) had an additional shedding episode after their initial lesion healed, lasting for a median of 2 days. CONCLUSIONS: A 1-day course of valacyclovir may be a convenient treatment for recurrent genital herpes and comparative trials are warranted.",
author = "Bavaro, {Joseph B.} and Linda Drolette and Koelle, {David M.} and Jennifer Almekinder and Terri Warren and Stephen Tyring and Anna Wald",
year = "2008",
month = "4",
day = "1",
doi = "10.1097/OLQ.0b013e31815e4190",
language = "English (US)",
volume = "35",
pages = "383--386",
journal = "Sexually Transmitted Diseases",
issn = "0148-5717",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. / Bavaro, Joseph B.; Drolette, Linda; Koelle, David M.; Almekinder, Jennifer; Warren, Terri; Tyring, Stephen; Wald, Anna.

In: Sexually Transmitted Diseases, Vol. 35, No. 4, 01.04.2008, p. 383-386.

Research output: Contribution to journalArticle

TY - JOUR

T1 - One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection

AU - Bavaro, Joseph B.

AU - Drolette, Linda

AU - Koelle, David M.

AU - Almekinder, Jennifer

AU - Warren, Terri

AU - Tyring, Stephen

AU - Wald, Anna

PY - 2008/4/1

Y1 - 2008/4/1

N2 - OBJECTIVES: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration and severity of genital herpes recurrences and to measure the frequency of viral shedding episodes subsequent to antiviral therapy. STUDY DESIGN: In an open-label pilot study, patients with recurrent genital herpes simplex virus 2 (HSV-2) infection were given a 1-day course of valacyclovir (2000 mg given by mouth twice daily) to be taken at the first sign of recurrence or prodrome. Participants maintained diaries of signs and symptoms and collected genital swabs for viral culture while lesions persisted and HSV DNA PCR for 14 days after initiating treatment. RESULTS: Ninety (78%; 41 men, 49 women) of the 115 enrolled persons experienced either a lesional recurrence or prodrome. Seventy- seven (86%) participants developed lesions; 4 (5%) participants experienced a second lesional recurrence during the 14-day study period. The median lesion duration was 5 days, episode duration was 5 days, and pain duration was 3 days. Viral shedding was detected in 60 persons by PCR and 31 persons by culture. Shedding detected by culture lasted for a median of 2 days, and shedding detected by PCR lasted for a median of 3 days. Of 60 participants with viral shedding, 14 (23%) had an additional shedding episode after their initial lesion healed, lasting for a median of 2 days. CONCLUSIONS: A 1-day course of valacyclovir may be a convenient treatment for recurrent genital herpes and comparative trials are warranted.

AB - OBJECTIVES: To evaluate the efficacy of a 1-day course of valacyclovir in reducing the duration and severity of genital herpes recurrences and to measure the frequency of viral shedding episodes subsequent to antiviral therapy. STUDY DESIGN: In an open-label pilot study, patients with recurrent genital herpes simplex virus 2 (HSV-2) infection were given a 1-day course of valacyclovir (2000 mg given by mouth twice daily) to be taken at the first sign of recurrence or prodrome. Participants maintained diaries of signs and symptoms and collected genital swabs for viral culture while lesions persisted and HSV DNA PCR for 14 days after initiating treatment. RESULTS: Ninety (78%; 41 men, 49 women) of the 115 enrolled persons experienced either a lesional recurrence or prodrome. Seventy- seven (86%) participants developed lesions; 4 (5%) participants experienced a second lesional recurrence during the 14-day study period. The median lesion duration was 5 days, episode duration was 5 days, and pain duration was 3 days. Viral shedding was detected in 60 persons by PCR and 31 persons by culture. Shedding detected by culture lasted for a median of 2 days, and shedding detected by PCR lasted for a median of 3 days. Of 60 participants with viral shedding, 14 (23%) had an additional shedding episode after their initial lesion healed, lasting for a median of 2 days. CONCLUSIONS: A 1-day course of valacyclovir may be a convenient treatment for recurrent genital herpes and comparative trials are warranted.

UR - http://www.scopus.com/inward/record.url?scp=41149099141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149099141&partnerID=8YFLogxK

U2 - 10.1097/OLQ.0b013e31815e4190

DO - 10.1097/OLQ.0b013e31815e4190

M3 - Article

C2 - 18362859

AN - SCOPUS:41149099141

VL - 35

SP - 383

EP - 386

JO - Sexually Transmitted Diseases

JF - Sexually Transmitted Diseases

SN - 0148-5717

IS - 4

ER -